Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : Acquires Arctos Medical to Expand Optogenetics Portfolio

09/21/2021 | 03:40am EDT


© MT Newswires 2021
All news about NOVARTIS AG
10/14VC DAILY : Sprinter Health Collects $33 Million to Join Home-Healthcare Race
DJ
10/14NOVARTIS AG : Goldman Sachs reiterates its Buy rating
MD
10/14NOVARTIS' : Kesimpta Shows Stable Antibody Levels in Patients of Phase 3b Extension Study
MT
10/14NOVARTIS : Says Diabetic Macular Edema Drug Applications Accepted by FDA, EMA
MT
10/14NOVARTIS' : Multiple Sclerosis Therapy Shows Preservation of Immunoglobulin Levels in Rela..
MT
10/14NOVARTIS : Kesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels an..
PU
10/13NOVARTIS' : Supplemental Biologics License Application for Beovu Accepted in US, EU
MT
10/13NOVARTIS : announces FDA and EMA filing acceptances of Beovu® for patients with diabetic m..
PU
10/12NOVARTIS AG : Bernstein sticks Neutral
MD
10/11GLOBAL MARKETS LIVE : Facebook, Apple, KKR, Adler, Roche...
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 52 021 M - -
Net income 2021 9 854 M - -
Net Debt 2021 23 500 M - -
P/E ratio 2021 18,4x
Yield 2021 3,92%
Capitalization 186 B 186 B -
EV / Sales 2021 4,03x
EV / Sales 2022 3,77x
Nbr of Employees 109 000
Free-Float 87,0%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 83,31 $
Average target price 101,67 $
Spread / Average Target 22,0%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-8.03%186 330
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657